Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis
Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis
The purpose of this research study to find out if a drug called OctreoScan or DOTATATE can
 help doctors diagnose people with cardiac sarcoidosis better.

 OctreoScan and DOTATATE are both approved by the U.S. Food and Drug Administration (FDA) to
 diagnose certain tumors.
Inclusion Criteria:

 -  Individuals aged 18 or older

 -  Documentation of biopsy-proven sarcoidosis OR patients with typical findings on FDG
 PET and MRI without previous biopsy

 -  Clinical suspicion of cardiac involvement defined as the presence of any of the
 following: high-degree A-V nodal block, complete bundle branch block, reduced left or
 right ventricular systolic function, any cardiac arrhythmia, and/or unexplained chest
 pain, dyspnea or syncope

 -  PET/CT imaging demonstrating abnormal myocardial FDG uptake consistent with active
 inflammatory myocardium.

 Exclusion Criteria:

 -  Initiation of steroids or any other immunosuppressive medication(s) following the
 completion of FDG-PET, as these medications, in theory, may subsequently suppress
 OctreoScan or DOTATATE uptake in the heart.

 -  Patients with history of neuroendocrine tumors (specially insulinomas)

 -  Patients taking the medication Octreotide

 -  Patients on total parenteral nutrition (TPN)

 -  Women who are pregnant or breastfeeding